DUBLIN--(BUSINESS WIRE)--The "Drug
analysis: Bosulif" drug pipelines has been added to ResearchAndMarkets.com's
offering.
Bosulif (bosutinib; Pfizer) is a kinase inhibitor
that targets the BCR-ABL kinase and also inhibits the Src-family kinases
that include Src, Lyn, and Hck. The BCR-ABL kinase is upregulated in the
presence of an abnormal BCR-ABL fusion protein, which is a common
hallmark of chronic myeloid leukemia (CML). Over expression of specific
Src kinases is associated with Gleevec-resistant CML phenotypes. In
mice, treatment with Bosulif reduced the size of CML tumors relative to
controls and inhibited growth of murine myeloid tumors expressing
several Gleevec-resistant forms of BCR-ABL.
Bosulif was the
fourth tyrosine kinase inhibitor (TKI) to enter the CML market and is
most commonly used in the third-line setting. Bosulif benefits from its
activity against CML mutations that confer resistance to Gleevec
(imatinib; Novartis), Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka),
and Tasigna (nilotinib; Novartis). The drug failed to demonstrate a
statistically significant difference in cytogenetic response versus
Gleevec in the Phase III BELA trial; however, Pfizer is making a second
attempt in first-line CML with the Phase III BFORE trial. Nonetheless,
Bosulif's late entry into the CML market will continue to hinder its
uptake.
Key Topics Covered:
List
of Figures
Figure 1: Bosulif for CML - SWOT analysis
Figure
2: Drug assessment summary of Bosulif for CML
Figure 3: Drug
assessment summary of Bosulif for CML
List of Tables
Table
1: Bosulif drug profile
Table 2: Bosulif pivotal trial data in CML
Table
3: Bosulif late-phase trial data in CML
For more information
about this drug pipelines report visit https://www.researchandmarkets.com/research/mcd8bj/bosulif_drug?w=4
Bosulif Drug Analysis 2018: A Kinase Inhibitor that Targets the BCR-ABL Kinase and Also Inhibits the SRC-Family Kinases that Include SRC, LYN, and HCK - ResearchAndMarkets.com
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs